Please login to the form below

Not currently logged in

S-A to outline reorganisation

French firm sanofi-aventis will announce plans to restructure its R&D business within weeks

Sanofi-aventis will reveal, in a matter of weeks, restructuring plans to rationalise decision-making and boost efficiency in R&D, the company's chief executive has said.

In an interview with Reuters, Chris Viehbacher said he would address how the company could provide 'more latitude for creativity' among the workforce, developing them scientifically and encouraging collaboration.

As part of the restructure, Viehbacher said he would extend existing collaborative deals with universities and government-funded institutions.

The company is due to meet unions next week to discuss the implications of the planned reorganisation on staff. Viehbacher has declined to comment on potential job losses other than the 927 job cuts announced in October 2008.

With €4bn in the coffers, Viehbacher reiterated the firm's plans to use its free cash to further expand the business through acquisition. He said the company was committed to diversifying through the purchase of small or mid-sized companies in areas including vaccines, over-the-counter medicines and generics. In particular he voiced an interest in the emerging markets of Eastern Europe, Latin America and Asia.

Viehbacher said that sanofi-aventis would use the foothold Zentiva has in Eastern Europe as a base for generics expansion in the region. Sanofi-aventis acquired the Czech firm earlier this year to gain presence in the generics markets of central and Eastern Europe.

He said the French company was now look to establish a similar generics platform in Latin America, where sanofi-aventis acquired Medley in Brazil and Laboratorios Kendrick in Mexico. The company is also looking to move into Asia.

"If we can find other acquisition opportunities like Zentiva elsewhere, we will do that," Viehbacher told Reuters.

25th June 2009


Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...